Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community - PubMed (original) (raw)
Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community
C J Ostgren et al. Diabetes Obes Metab. 2004 Sep.
Abstract
Aim: To explore the prevalence of atrial fibrillation in patients with hypertension and type 2 diabetes and to identify possible mechanisms for the development of atrial fibrillation.
Methods: A community-based, cross-sectional observational study was conducted in the primary health care in Skara, Sweden, and 1739 subjects (798 men, 941 women) were surveyed. Patients were categorized as those with hypertension only (n = 597); those with both hypertension and type 2 diabetes (n = 171), and those with type 2 diabetes only (n = 147). In the reference population, 824 normotensive subjects without diabetes were identified and used as controls. Participants were examined for cardiovascular risk factors including fasting blood glucose, serum insulin, blood pressure, lipids and anthropometric measures. Resting electrocardiogram (ECG) was recorded and Minnesota-coded. Insulin resistance was measured by the homeostasis model assessment (HOMA).
Results: Age-adjusted prevalence of atrial fibrillation was 2% in patients with hypertension only, 6% in patients with both hypertension and type 2 diabetes, 4% in patients with type 2 diabetes only and 2% in controls, respectively. Age and sex adjusted odds ratios (OR) (95% CI) were; hypertension 0.7 (0.30-1.5), combined hypertension and type 2 diabetes 3.3 (1.6-6.7), and type 2 diabetes 2.0 (0.9-4.7). The association with combined hypertension and type 2 diabetes remained significant when adjusted for cardiovascular disease (CVD) risk factors and body mass index (BMI), was attenuated with adjustment for ischemic ECG; 2.4 (1.1-5.0) and lost significance with adjustment for insulin resistance; 1.3 (0.5-3.1).
Conclusions: Atrial fibrillation is associated with the combined occurrence of type 2 diabetes and hypertension. Insulin resistance may be a common underlying mechanism.
Copyright 2004 Blackwell Publishing Ltd
Similar articles
- Effects of orlistat on obesity-related diseases - a six-month randomized trial.
Guy-Grand B, Drouin P, Eschwège E, Gin H, Joubert JM, Valensi P. Guy-Grand B, et al. Diabetes Obes Metab. 2004 Sep;6(5):375-83. doi: 10.1111/j.1462-8902.2004.00359.x. Diabetes Obes Metab. 2004. PMID: 15287931 Clinical Trial. - HOMA-estimated insulin resistance is associated with hypertension in Iranian diabetic and non-diabetic subjects.
Esteghamati A, Khalilzadeh O, Abbasi M, Nakhjavani M, Novin L, Esteghamati AR. Esteghamati A, et al. Clin Exp Hypertens. 2008 Jul;30(5):297-307. doi: 10.1080/10641960802269919. Clin Exp Hypertens. 2008. PMID: 18633753 - Abdominal obesity and insulin resistance in patients with type 2 diabetes in a Swedish community. Skaraborg hypertension and diabetes project.
Bari MR, Ostgren CJ, Råstam L, Lindblad U. Bari MR, et al. Scand J Prim Health Care. 2006 Dec;24(4):211-7. doi: 10.1080/02813430601035290. Scand J Prim Health Care. 2006. PMID: 17118860 - Evidence that prehypertension is a risk factor for Type 2 diabetes.
Everett CJ, Frithsen IL. Everett CJ, et al. Expert Rev Cardiovasc Ther. 2010 Mar;8(3):335-7. doi: 10.1586/erc.09.181. Expert Rev Cardiovasc Ther. 2010. PMID: 20222812 Review. - Diabetes and syndrome X in hypertension--population aspects.
Nilsson P. Nilsson P. J Hum Hypertens. 1996 Feb;10 Suppl 1:S81-4. J Hum Hypertens. 1996. PMID: 8965297 Review.
Cited by
- The impact of age on the epidemiology of atrial fibrillation hospitalizations.
Naderi S, Wang Y, Miller AL, Rodriguez F, Chung MK, Radford MJ, Foody JM. Naderi S, et al. Am J Med. 2014 Feb;127(2):158.e1-7. doi: 10.1016/j.amjmed.2013.10.005. Epub 2013 Oct 16. Am J Med. 2014. PMID: 24332722 Free PMC article. - MiR-21-3p Inhibits Adipose Browning by Targeting FGFR1 and Aggravates Atrial Fibrosis in Diabetes.
Pan JA, Lin H, Yu JY, Zhang HL, Zhang JF, Wang CQ, Gu J. Pan JA, et al. Oxid Med Cell Longev. 2021 Aug 25;2021:9987219. doi: 10.1155/2021/9987219. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34484568 Free PMC article. - Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL. He YL. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. doi: 10.2165/11598080-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22339447 Review. - The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.
Iravanian S, Dudley SC Jr. Iravanian S, et al. Heart Rhythm. 2008 Jun;5(6 Suppl):S12-7. doi: 10.1016/j.hrthm.2008.02.025. Epub 2008 Mar 4. Heart Rhythm. 2008. PMID: 18456194 Free PMC article. Review. - Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study.
Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Seyed Ahmadi S, et al. Cardiovasc Diabetol. 2020 Jan 18;19(1):9. doi: 10.1186/s12933-019-0983-1. Cardiovasc Diabetol. 2020. PMID: 31954408 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical